Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines
- PMID: 8346003
- DOI: 10.1097/00006454-199307000-00009
Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines
Abstract
Rates of invasive Haemophilus influenzae type b (Hib) disease in children decreased very rapidly after licensure of Hib conjugate vaccines. A role for a vaccine-related reduction in nasopharyngeal carriage of Hib has been suggested. We studied oropharyngeal carriage of Hib and vaccination rates in a population of 2- to 5-year-old children in metropolitan Atlanta. Among 584 children 75% were vaccinated with an Hib conjugate vaccine, 17% had not been vaccinated and 8% had no vaccination records available. Forty-one percent of the children were colonized with H. influenzae. One child was colonized with Hib. Hib carriage (0.17%; upper 95% confidence interval boundary, 0.97%) was substantially lower than the estimates of Hib carriage from prior studies of children who had not received Hib conjugate vaccines. Our data are consistent with a decline in Hib carriage induced by widespread use of conjugate Hib vaccines, which may have contributed to the decline of Hib disease in United States children.
Similar articles
-
Vaccination with Haemophilus influenzae type b meningococcal protein conjugate vaccine reduces oropharyngeal carriage of Haemophilus influenzae type b among American Indian children.Pediatr Infect Dis J. 1993 Jul;12(7):593-9. doi: 10.1097/00006454-199307000-00010. Pediatr Infect Dis J. 1993. PMID: 8346004
-
Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine.J Infect Dis. 1991 Nov;164(5):982-6. doi: 10.1093/infdis/164.5.982. J Infect Dis. 1991. PMID: 1940479
-
Haemophilus influenzae type b carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide-CRM197 (HbOC) conjugate vaccine.Pediatr Infect Dis J. 1993 Jun;12(6):478-84. doi: 10.1097/00006454-199306000-00005. Pediatr Infect Dis J. 1993. PMID: 8345980
-
Haemophilus influenzae type b polysaccharide-protein conjugate vaccines in children.Curr Opin Pediatr. 1993 Feb;5(1):55-9. doi: 10.1097/00008480-199302000-00009. Curr Opin Pediatr. 1993. PMID: 8374627 Review.
-
Haemophilus influenzae type b disease in the era of conjugate vaccines: critical factors for successful eradication.Expert Rev Vaccines. 2020 Oct;19(10):903-917. doi: 10.1080/14760584.2020.1825948. Epub 2020 Oct 10. Expert Rev Vaccines. 2020. PMID: 32962476 Review.
Cited by
-
Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates.Clin Microbiol Rev. 2000 Apr;13(2):302-17. doi: 10.1128/CMR.13.2.302. Clin Microbiol Rev. 2000. PMID: 10756001 Free PMC article. Review.
-
Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria.J Clin Pathol. 2004 Oct;57(10):1015-21. doi: 10.1136/jcp.2004.016253. J Clin Pathol. 2004. PMID: 15452151 Free PMC article. Review.
-
Why we need a vaccine for non-typeable Haemophilus influenzae.Hum Vaccin Immunother. 2016 Sep;12(9):2357-61. doi: 10.1080/21645515.2016.1174354. Epub 2016 May 12. Hum Vaccin Immunother. 2016. PMID: 27171854 Free PMC article.
-
Immunologic response to Haemophilus influenzae type b (Hib) conjugate vaccine and risk factors for carriage among Hib carriers and noncarriers in Southwestern Alaska.Clin Vaccine Immunol. 2006 Jun;13(6):620-6. doi: 10.1128/CVI.00077-06. Clin Vaccine Immunol. 2006. PMID: 16760318 Free PMC article. Clinical Trial.
-
Cost-benefit analysis of Haemophilus influenzae type b vaccination in children in Spain.Pharmacoeconomics. 1999 Jan;15(1):75-83. doi: 10.2165/00019053-199915010-00005. Pharmacoeconomics. 1999. PMID: 10345159
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical